Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 5,397 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Random Match Clear all
Completed Phase 2 Interventional Results available

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

NCT02185040
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
CC-220, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
35
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 28, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones

NCT00576589
View directory record Official record
Conditions
Obesity
Interventions
CE-326,597, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
12
States / cities
Anniston, Alabama • Phoenix, Arizona • Anaheim, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2010 · Synced Oct 28, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis

NCT04886258
View directory record Official record
Conditions
Symptomatic Knee Osteoarthritis
Interventions
DFV890, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 80 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Phoenix, Arizona • El Cajon, California • Colorado Springs, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 28, 2026, 1:19 PM EDT
Recruiting Not applicable Interventional

The Impact of Melatonin Lotion on Sleep and Mental Health

NCT06768749
View directory record Official record
Conditions
Sleep Problems, Depressive Disorder and Anxiety Disorders
Interventions
Melatonin lotion, Placebo lotion
Other
Lead sponsor
University of Redlands
Other
Eligibility
18 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Redlands, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 28, 2026, 1:19 PM EDT
Completed Phase 3 Interventional Results available

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

NCT02294058
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ozanimod, Interferon beta-1a, Placebo to ozanimod, Placebo to interferon beta-1a
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 28, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

ELND005 in Patients With Mild to Moderate Alzheimer's Disease

NCT00568776
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Placebo Control, ELND005
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
50
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 28, 2026, 1:19 PM EDT
Completed Phase 3 Interventional Results available

Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary

NCT01552343
View directory record Official record
Conditions
Nocturia
Interventions
Desmopressin, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Aventura, Florida • DeLand, Florida • Peoria, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 28, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment

NCT01082640
View directory record Official record
Conditions
Renal Impairment
Interventions
Febuxostat, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
58
States / cities
Birmingham, Alabama • Peoria, Arizona • Sierra Vista, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2013 · Synced Oct 28, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy

NCT04985760
View directory record Official record
Conditions
HIV Infections
Interventions
Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant
Biological
Lead sponsor
Madhu Chhanda Choudhary
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 28, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers

NCT02413255
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-020, TAK-020 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 28, 2026, 1:19 PM EDT
Terminated Phase 2 Interventional Results available

MLE4901 vs. Placebo for the Treatment of PCOS

NCT02865915
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS)
Interventions
MLE4901, Placebo
Drug
Lead sponsor
Millendo Therapeutics US, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
31
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Oceanside, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 28, 2026, 1:19 PM EDT
Terminated Phase 3 Interventional

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

NCT04729608
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer
Interventions
Batiraxcept, Paclitaxel, Placebo
Drug · Other
Lead sponsor
Aravive, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
84
States / cities
Mobile, Alabama • Burbank, California • Los Angeles, California + 74 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 28, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795

NCT04844450
View directory record Official record
Conditions
Fatty Liver Disease
Interventions
JNJ-75220795, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Hollywood, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 28, 2026, 1:19 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema

NCT01994291
View directory record Official record
Conditions
Macular Edema, Diabetic
Interventions
Ranibizumab, Placebo, PF-04634817, Masked Sham Therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 28, 2026, 1:19 PM EDT
Active, not recruiting Phase 2 Interventional

Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis

NCT07332091
View directory record Official record
Conditions
Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
Interventions
Vamifeport, Placebo
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
20
States / cities
Gilbert, Arizona • San Diego, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 28, 2026, 1:19 PM EDT
Terminated Phase 2 Interventional Results available

A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA

NCT05462990
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
QUC398, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Tampa, Florida • Boston, Massachusetts • Morehead City, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 28, 2026, 1:19 PM EDT
Active, not recruiting Phase 2 Interventional

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

NCT05588843
View directory record Official record
Conditions
Colitis Ulcerative
Interventions
SAR443122, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Lancaster, California • Atlanta, Georgia • Evanston, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 28, 2026, 1:19 PM EDT
Recruiting Phase 3 Interventional

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

NCT06807268
View directory record Official record
Conditions
Eczema
Interventions
Abrocitinib, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 11 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
13
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)

NCT04624243
View directory record Official record
Conditions
Schizophrenia
Interventions
Elpipodect, Risperidone, Placebo to MK-8189, Placebo to risperidone
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
35
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 28, 2026, 1:19 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

NCT07486960
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Tulisokibart, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
18
States / cities
Sun City, Arizona • Tucson, Arizona • Riverside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-human Study of MRT-6160 in Healthy Subjects

NCT06597799
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MRT-6160, Placebo
Drug
Lead sponsor
Monte Rosa Therapeutics, Inc
Industry
Eligibility
19 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 28, 2026, 1:19 PM EDT
Active, not recruiting Phase 2 Interventional

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

NCT06602193
View directory record Official record
Conditions
Parkinson Disease
Interventions
BIIB122 225 mg, BIIB122-Matching Placebo
Drug · Other
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boca Raton, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 28, 2026, 1:19 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

NCT02340221
View directory record Official record
Conditions
Breast Cancer
Interventions
Taselisib, Placebo, Fulvestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
16
States / cities
Tucson, Arizona • Atlanta, Georgia • Marietta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 28, 2026, 1:19 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally

NCT05098938
View directory record Official record
Conditions
Recurrent Herpes Labialis
Interventions
Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
2,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 28, 2026, 1:19 PM EDT